Biosysen Limited (BIOSYSEN) reported a substantial expansion in its share base for the month ended 30 September 2026, driven by the completion of a non-underwritten rights issue on 8 September.

The rights issue, executed on a one-for-two basis at HKD 0.068 per share, generated 596.53 million new ordinary shares. This raised the company’s issued share count from 1.19 billion to 1.79 billion, while treasury shares remained at zero.

Authorised capital was unchanged at 10.00 billion shares with a par value of HKD 0.01, equivalent to HKD 100.00 million. Post-transaction, the company confirmed that it continued to meet the Hong Kong Stock Exchange’s minimum public-float requirement of 25%.

Biosysen also maintains an unlisted HKD 50.00 million zero-coupon convertible bond maturing in 2031, carrying a conversion price of HKD 0.129. No conversions occurred during September, leaving the full bond principal outstanding and convertible.

The company’s board and secretary affirmed that all share issuances complied with applicable listing rules, regulatory requirements and corporate authorisations.